- Piramal Pharma Solutions aggiunge alla sua offerta globale nuove tecnologie e risorse per quanto riguarda le molecole grandi, tra cui vaccini e terapia genica
MINSK, Bielorussia, 8 dicembre 2021 /PRNewswire/ -- Come un'impresa situata nel CBIP, la New Era Biotechnology Co., Ltd. ha partecipato alla quarta edizione del China International Import Expo (CIIE) la quale si èinaugurata a Shanghai il 5 novembre 2021.
THE HAGUE, Netherlands, Oct. 14, 2021 /PRNewswire/ -- Dutch biotechnology company Micreos has recruited Matt Regan as CEO of its new Pharmaceutical business that will be based in Switzerland. Following rapid growth, Micreos is preparing to spin-out its Pharmaceutical business into a separate company as per January 2022 to directly access the capital markets. This will help to fund pipeline development to progress its highly innovative, targeted antibacterial technology platform into pharmaceutica...
World Leader in Fibroblast Technology Advances Intellectual Property Position with their 250th Patent Filed Today
PRAGUE, Nov. 4, 2020 /PRNewswire/ -- Zentiva has received the 2020 Global Generics & Biosimilars Bulletin Award in the category of EMEA Acquisition of the year. In Q2 2020, during the peak of the first wave of the COVID-19 crisis, Zentiva completed the acquisition of Alvogen CEE that brought together two of the leading branded generic and OTC businesses in the CEE region. This acquisition is already showing indicators of success and is supporting the journey of Zentiva and its strong ambition t...
Horizon's TEPEZZA® (teprotumumab-trbw) treatment will be produced from AGC Biologics' new facility in Boulder, CO
WAALWIJK, Netherlands, Aug. 26, 2020 /PRNewswire/ -- RoboPharma announced today the company has been acquired by Capsa Healthcare, a worldwide innovator in healthcare delivery solutions for hospitals, senior care settings, and retail pharmacy providers. Becoming an integral segment within Capsa Healthcare provides RoboPharma deeper resources to further develop its existing and additional new-to-market pharmacy automation solutions.
WETTEREN, Belgium, Aug. 13, 2020 /PRNewswire/ -- Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of biopharmaceutical contract development and manufacturing services, is pleased to announce a major expansion of small molecule manufacturing capabilities with the addition of a new production facility in Visakhapatnam, India. Construction of the 8,500 square meter facility began at the end of July 2020 and is expected to be completed mid-2022.
AGC Biologics adds leading-edge cell & gene therapy company in Milan, Italy
